Biogen Inc. (BIIB) retreated with the stock falling -0.21% or $-0.58 to close at $273.24 on active trading volume of 2.51M compared its three months average trading volume of 1.82M. The Cambridge Massachusetts 02142 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 5.14% up for the period and down by -3.65% so far this year. With price target of $340.46 and a 22.52% rebound from 52-week low, Biogen Inc. has plenty of upside potential, making it a hold with a view buy.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat hemophilia A for control of bleeding episodes; ALPROLIX to treat hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL); GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company’s products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer’s disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer’s disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS – DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson’s disease; and BIIB063 for sjogren’s syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc.; and an agreement with Siemens Healthineers to develop new magnetic resonance imaging tools for multiple sclerosis. It offers products through its sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
E*TRADE Financial Corporation (ETFC) had a light trading with around 2.47M shares changing hands compared to its three month average trading volume of 2.95M. The stock traded between $36.74 and $37.33 before closing at the price of $36.99 with 0.74% change on the day. The New York New York 10020 based company is currently trading 88.63% above its 52 week low of $19.61 and -1.07% below its 52 week high of $37.39. Both the RSI indicator and target price of and $40.41 respectively, lead us to believe that it could rise over the coming weeks.
E*TRADE Financial Corporation, a financial services company, provides brokerage and related products and services primarily to individual retail investors under the E*TRADE Financial brand name. It operates through two segments, Trading and Investing, and Balance Sheet Management. The Trading and Investing segment offers retail brokerage products and services, investor-focused banking products, and corporate services. The Balance Sheet Management segment manages asset allocation; loans previously originated by the company or purchased from third parties; deposits and customer payables; and credit, liquidity, and interest rate risk. The company provides its services to customers through digital platforms; and a network of customer service representatives and financial consultants through phone, email, and online at two branches, as well as in person through 30 branches across the United States. E*TRADE Financial Corporation was incorporated in 1982 and is headquartered in New York, New York.
The PNC Financial Services Group, Inc. (PNC) saw its value increase by 1.98% as the stock gained $2.35 to finish the day at a closing price of $121.01. The stock was lighter in trading and has fluctuated between $77.4-$121.33 per share for the past year. The shares, which traded within a range of $119.53 to $121.19 during the day, are up by 30.68% in the past three months and up by 47.91% over the past six months. It is currently trading 3.12% above its 20 day moving average and 6.23% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $124.23 a share over the next twelve months. The current relative strength index (RSI) reading is 61.17.The technical indicator lead us to believe there will be no major movement any time soon, hold.
The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States and internationally. The company’s Retail Banking segment offers deposit, lending, brokerage, investment management, and cash management services to consumer and small business customers through branch network, ATMs, call centers, online banking, and mobile channels. As of March 31, 2016, this segment operated a network of 2,613 branches and 8,940 ATMs. Its Corporate & Institutional Banking segment provides secured and unsecured loans, letters of credit, equipment leases, cash and investment management, receivables management, disbursement and funds transfer, information reporting, trade services, foreign exchange, derivatives, securities, loan syndications, mergers and acquisitions advisory, equity capital markets advisory, and related services for corporations, government, and not-for-profit entities. This segment also offers commercial loan servicing, and real estate advisory and technology solutions for the commercial real estate finance industry. The company’s Asset Management Group segment provides investment and retirement planning, customized investment management, private banking, tailored credit solutions, and trust management and administration for individuals and their families; multi-generational family planning products; and mutual funds and institutional asset management services. Its Residential Mortgage Banking segment offers first lien residential mortgage loans. The company’s BlackRock segment provides investment and risk management services to institutional and retail clients. Its Non-Strategic Assets Portfolio segment offers consumer residential mortgage, brokered home equity loans, and lines of credit, as well as commercial real estate loans and leases. The PNC Financial Services Group, Inc. was founded in 1922 and is headquartered in Pittsburgh, Pennsylvania.